We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Deciphera

News List

Deciphera gets FDA nod for Qinlock to treat fourth-line gastrointestinal stromal tumour pharmaceutical-business-review
May 20, 2020
Deciphera Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for its Qinlock (ripretinib) to treat fourth-line gastrointestinal stromal tumour (GIST).
Deciphera Announces Positive Results from Ripretinib Study americanpharmaceuticalreview
August 14, 2019
Deciphera Pharmaceuticals announced positive top-line data from the INVICTUS pivotal Phase 3 clinical study of ripretinib, a broad-spectrum KIT and PDGFRα inhibitor, in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors (GIST).
Deciphera licenses cancer drug ripretinib to Zai Lab in China pharmaceutical-technology
June 13, 2019
US-based Deciphera Pharmaceuticals has signed an exclusive licence agreement with biopharmaceutical company Zai Lab to develop and commercialise cancer therapeutic ripretinib in Greater China.
Deciphera expands cancer trial after seeing early data fiercebiotech
January 04, 2019
Deciphera Pharmaceuticals has posted data from a phase 1 trial of its small molecule switch control inhibitor of CSF1R, DCC-3014. The early-phase data have emboldened Deciphera to expand the trial to include patients with....